- Home
- EGHT vs NBTX Comparison
EGHT vs NBTX Comparison
Compare EGHT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGHT
- NBTX
- Stock Information
- Founded
- EGHT 1987
- NBTX 2003
- Country
- EGHT United States
- NBTX France
- Employees
- EGHT N/A
- NBTX N/A
- Industry
- EGHT EDP Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- EGHT Technology
- NBTX Health Care
- Exchange
- EGHT Nasdaq
- NBTX Nasdaq
- Market Cap
- EGHT 250.2M
- NBTX 235.6M
- IPO Year
- EGHT 1997
- NBTX 2020
- Fundamental
- Price
- EGHT $1.98
- NBTX $5.11
- Analyst Decision
- EGHT Buy
- NBTX Strong Buy
- Analyst Count
- EGHT 6
- NBTX 2
- Target Price
- EGHT $2.83
- NBTX $11.50
- AVG Volume (30 Days)
- EGHT 880.5K
- NBTX 13.2K
- Earning Date
- EGHT 10-30-2024
- NBTX 10-15-2024
- Dividend Yield
- EGHT N/A
- NBTX N/A
- EPS Growth
- EGHT N/A
- NBTX N/A
- EPS
- EGHT N/A
- NBTX N/A
- Revenue
- EGHT $723,565,000.00
- NBTX $45,220,186.00
- Revenue This Year
- EGHT $0.85
- NBTX N/A
- Revenue Next Year
- EGHT $2.15
- NBTX N/A
- P/E Ratio
- EGHT N/A
- NBTX N/A
- Revenue Growth
- EGHT N/A
- NBTX 526.17
- 52 Week Low
- EGHT $1.51
- NBTX $4.14
- 52 Week High
- EGHT $3.92
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- EGHT 50.41
- NBTX 49.14
- Support Level
- EGHT $1.89
- NBTX $4.97
- Resistance Level
- EGHT $2.20
- NBTX $5.38
- Average True Range (ATR)
- EGHT 0.10
- NBTX 0.35
- MACD
- EGHT 0.02
- NBTX 0.01
- Stochastic Oscillator
- EGHT 37.14
- NBTX 41.53
About EGHT 8x8 Inc
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.